The funds will support two Phase 2a clinical trials for the drug candidate CIL001, targeting cochlear synaptopathy (a leading cause of difficulty understanding speech in noise, tinnitus, and hyperacusis), as well as the advancement of preclinical development for the candidate CIL003. The company will enhance its R&D platform capabilities and establish new strategic partnerships to […]
July 25, 2024 – (PRNewswire) – ObvioHealth, a global digital clinical trials company, announces a new strategic investment by Guardant Health, Inc., a leading precision oncology company offering liquid and tissue biopsy tests across the cancer research and care continuum. The alliance strengthens ObvioHealth’s domain expertise in oncology and enables streamlined deployment of oncology clinical […]
June 18, 2024 – (Forbes Australia) – Founder and CEO Mimi Tang has spent almost three decades working in allergy immunology. For much of that time, she was unsatisfied with the common approach – avoid the allergen and turn to the EpiPen in an emergency. But, after an initial trial in 2015 showed hope for […]
SINGAPORE, May 26, 2023 – SPRIM Global Investments (SPRIM), a leading health sciences investment firm, completed an equity investment in VCTC Limited, a UK-based specialist clinical trial site. SPRIM funding will enable VCTC to expedite growth through expansion of services and access to wider cross-portfolio opportunities. This investment is part of SPRIM’s strategy to build […]
Travecta Therapeutics, announces today it has raised an additional $12 million in financing, closing its Series A round at a total of $27 million.
PHILADELPHIA–(BUSINESS WIRE)–Vanteres, an innovative biotech company leveraging its biomedical research expertise to develop actively transported lysophospholipids, announces new evidence that demonstrates the critical role of LPC-DHA in normal fetal and infant brain development.